Macrophage inflammatory proteins as markers of severe COVID-19


DOI: https://dx.doi.org/10.18565/epidem.2022.12.1.35-8

Grishaeva A.A., Ponezheva Zh.B., Chanyshev M.D., Aleshina N.I., Myasnikova M.A., Krasnova S.V.

1) Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2) N.I. Pirogov Russian National Research Medical University, Moscow, Russia; 3) Infectious Disease Clinical Hospital Two, Moscow Healthcare Department, Moscow, Russia
COVID-19 infection is accompanied by the intensive secretion of cytokines, including macrophage inflammatory proteins (MIP-1A, MIP-1B), especially in patients with severe COVID-19.
Objective. To determine the serum concentration of MIP-1A and MIP-1B in patients with severe COVID-19.
Subjects and methods. Examinations were made in 49 patients with severe COVID-19 (a study group) and in 30 patients with moderate COVID-19 (a comparison group). The patients’ clinical and laboratory parameters were analyzed; the serum levels of macrophage inflammatory proteins (MIP-1A, MIP-1B) were studied by solid-phase ELISA.
Results. The excess level of MIP-1A was observed in 42 (84%) patients in the study group and in 3 (10%) in the comparison group; the mean concentrations of MIP-1A were 156.79 and 3.71 pg/ml, respectively. MIP-1B was detected in 48 (96%) patients in the study group and in 11 (36.7%) in the comparison group; the mean concentrations of MIP-1B were 152.62 and 7.53 pg/ml, respectively. The groups showed a statistically significant (p < 0.01) correlation between the MIP-1A and MIP-1B concentrations; Pearson’s correlation coefficient was 0.756. The ROC analysis determined the high potential of MIP-1A and MIP-1B as prognostic markers. At the same time, the area under the curve (AUC) is estimated to be 0.919, which indicates the possibility of using MIP-1A and MIP-1B as markers of disease severity.
Conclusion. Severe COVID-19 is accompanied by a more pronounced elevation in serum MIP-1A and MIP-1B, which allows these indicators to be considered as potential markers of the progression of COVID-19.
Keywords: MIP-1B, MIP-1A, SARS-CoV2, COVID-19, severe course, prognosis, mortality
Read entire article

Literature


  1. Соколова Е.В., Беляева В.В. Особенности использования термина «приверженность» в современной отечественной научно-практической литературе, посвященной инфекционным заболеваниям. Журнал инфектологии Приложение 1; 11(3): 94–7. Sokolova E.V., Belyaeva V.V. [Features of the use of the term «commitment» in modern Russian scientific and practical literature devoted to infectious diseases]. Journal Infectology 2019. Appendix 1; 11(3): 94–7. (In Russ.).

  2. Беляева В.В., Соколова Е.В. Технология консультирования в формировании приверженности при ВИЧинфекции: анализ научно-практических публикаций. Журнал инфектологии Приложение 1; 11(3): 123–4. Belyaeva V.V., Sokolova E.V. [Technology of counseling in the formation of commitment in HIV infection: analysis of scientific and practical publications]. Journal Infectology 2019. Appendix 1; 11(3): 123–4. (In Russ.).

  3. Москвичева М.Г., Кытманова Л.Ю., Дегтярев А.А. Организация работы по формированию и сохранению приверженности диспансерному наблюдению и лечению при ВИЧ-инфекции. Челябинск: Южно-Уральский государственный медицинский университет, 2014. 93 с. Moskvicheva M.G., Kytmanova L.Yu., Degtyarev A.A. [Organization of work on the formation and maintenance of adherence to dispensary monitoring and treatment for HIV infection]. Chelyabinsk: South Ural State Medical University, 2014. 93 p. (In Russ.)

  4. Кытманова Л.Ю., Дегтярев А.А., Москвичева М.Г. Работа мультипрофессиональной команды с пациентами, имеющими зависимость от психоактивных веществ, получающих антиретровирусную терапию. ВИЧ-инфекция и иммуносупрессия 2015; 7(1): 90–6. Kytmanova L.Yu., Degtyarev A.A., Moskvicheva M.G. [The work of a multiprofessional team with patients who are addicted to psychoactive substances receiving antiretroviral therapy]. HIV Infection and Immunosuppressive Disorders 2015; 7(1): 90–6. (In Russ.).

  5. Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., Шепель Р.Н., Драпкина О.М. Методические рекомендации «Приверженность к лекарственной терапии у больных хроническими неинфекционными заболеваниями. Решение проблемы в ряде клинических ситуаций». Профилактическая медицина 2020; 23(3): 2042–60. DOI: 10.17116/profmed20202303242 Lukina Yu.V., Kutishenko N.P., Martsevich S. Yu., Shepel R.N., Drapkina O.M. [Methodological recommendations «Adherence to drug therapy in patients with chronic noncommunicable diseases. Addressing the problem in a number of clinical situations»]. Profilakticheskaya Meditsina 2020; 23 (3): 2042–60. (In Russ.). DOI: 10.17116/profmed20202303242

  6. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г. и др. Национальные рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(3, приложение). 104 с. Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Ermak T.N., Kanestri V.G. et al. [National guidelines on treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection]. Epidemiоlоgy and infectious diseases. Current items 2021; 11(3, application). 104 р. (In Russ.).

  7. Беляева В.В., Козырина Н.В., Соколова Е.В., Семикова С.Ю., Галиуллин Н.И., Лебедева Е.П. и др. Анализ факторов риска нарушения приверженности диспансерному наблюдению и лечению ВИЧ-инфекции: оценка готовности следовать рекомендациям специалистов. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(3): 63–8. DOI: 10.18565/epidem.2021.11.3.63-8 Belyaeva V.V., Kozyrina N.V., Sokolova E.V., Semikova S.Y., Galiullin N.I., Lebedeva E.P. et al. [Analysis of risk factors for non-adherence to follow-up and treatment for HIV infection: assessment of readiness to follow specialists’ recommendations]. Epidemiоlоgy and infectious diseases. Current items 2021; 11(3): 63–8. (In Russ.). DOI: 10.18565/ epidem.2021.11.3.63-8


About the Autors

Antonina A. Grishaeva, Junior Researcher, Clinical Department of Infectious Pathology, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Moscow, Russia; antoninagrishaeva@yandex.ru; https://orcid.org/0000-0002-1326-9274
Zhanna B. Ponezheva, MD, Leading Researcher, Head, Clinical Department of Infectious Pathology, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; doktorim@mail.ru; https://orcid.org/0000-0002-6539-4878
Mikhail D. Chanyshev, Researcher, Laboratory of Molecular Oncology, N.I. Pirogov Russian National Research Medical University, Ministry of Healt of Russia, Moscow, Russia; chanish@mail.ru; https://orcid.org/0000-0002-6943-2915
Nina I. Aleshina, Cand. Med. Sci., Doctor of Clinical and Laboratory Diagnostics of the Clinical and Diagnostic Laboratory, Infectious Diseases Clinical Hospital № 2, Moscow, Russia; nina_aleshina@list.ru; https://orcid.org/0000-0001-5599-1970
Maria A. Myasnikova, Head, Department for Combating COVID-19, Infectious Diseases Clinical Hospital № 2, Moscow, Russia; Myasnykova@mail.ru
Svetlana V. Krasnova, Cand. Med. Sci., Chief Physician, Infectious Diseases Clinical Hospital № 2, Moscow, Russia; krasnovasv@ikb2.ru


Similar Articles

Back to Content

Бионика Медиа